•High-risk multi-agent drug resistant GTN is a life threatening disease.•Majority of choriocarcinomas show intense PD-L1 immunoreactivity.•Pembrolizumab increases antitumor activity.•Effectiveness of Pembrolizumab in treating patients with high-risk multi-agent drug resistant GTN.
No takes yet. Share an insight, caveat, or question.
Goldfarb et al. (2020) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: